Well Referenced

Tag: 5-alpha-reductase inhibitors

Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia

This 2018 randomized controlled trial evaluated sexual adverse events in 117 men aged 23–50 receiving dutasteride 0.5 mg daily for androgenetic alopecia. During the 24-week double-blind phase, sexual adverse events (impotence, decreased libido, ejaculation disorders) occurred in 16% of the dutasteride group versus 8% in the placebo group. In the

Read More »
June 26, 2025 No Comments

Androgenetic alopecia: an evidence-based treatment update

This 2014 systematic review published in the American Journal of Clinical Dermatology (PMID: 24848508) provides an evidence-based update on treatments for androgenetic alopecia (AGA) in both men and women. The review concludes that oral finasteride (1 mg/day) and topical minoxidil (2% or 5%) are the most effective and well-supported options,

Read More »
June 26, 2025 No Comments

Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects

This 2012 observational study published in the Journal of Clinical Psychiatry (PMID: 22939118) examined the mental health of 61 former finasteride users who developed persistent sexual side effects after discontinuation. Results showed that 75% of these men had depressive symptoms (BDI-II ≥ 14), and 44% reported suicidal thoughts—dramatically higher than

Read More »
June 26, 2025 No Comments

Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study

This 2012 randomized controlled trial published in the Journal of the Medical Association of Thailand (PMID: 23193746) evaluated the efficacy and safety of 3% minoxidil (MNX) versus a combination of 3% minoxidil and 0.1% finasteride (MFX) in 40 men with androgenetic alopecia (AGA) over 24 weeks. The MFX group showed

Read More »
June 26, 2025 No Comments

Persistent sexual side effects of finasteride for male pattern hair loss

This observational study explored persistent sexual side effects in 71 otherwise healthy men aged 21–46 who used finasteride for male pattern hair loss. Despite discontinuing the drug, participants reported prolonged issues, with 94% experiencing low libido, 92% reporting erectile dysfunction and decreased arousal, and 69% having difficulty with orgasm. On

Read More »
June 26, 2025 No Comments

Persistent sexual side effects of finasteride: could they be permanent?

This observational study published in the Journal of Sexual Medicine (2012, PMID: 22789024) evaluated 54 otherwise healthy young men who developed persistent sexual side effects after discontinuing finasteride, a 5-alpha-reductase inhibitor used for male pattern baldness. Despite an average of 14 months off the medication, 96% of participants reported ongoing

Read More »
June 26, 2025 No Comments

Post-finasteride syndrome: a surmountable challenge for clinicians

This review article explores Post-Finasteride Syndrome (PFS), a condition characterized by persistent sexual, neurological, physical, and psychological side effects that can occur during or after discontinuation of finasteride or dutasteride, commonly prescribed for androgenetic alopecia or benign prostatic hyperplasia. The review identifies significant adverse effects such as sexual dysfunction, depression,

Read More »
June 26, 2025 No Comments

Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study

This randomized controlled trial compared dutasteride (0.5 mg) and finasteride (1 mg) in men aged 18–40 with androgenetic alopecia (AGA) over 24 weeks. Dutasteride showed significantly superior results in increasing hair count and reducing hair miniaturization compared to finasteride, with similar safety profiles. Both medications had mild to moderate adverse

Read More »
June 26, 2025 No Comments